HC Wainwright Issues Positive Forecast for Xeris Biopharma (NASDAQ:XERS) Stock Price

Key Points

• HC Wainwright raised its price target on Xeris Biopharma to $18 from $10 and maintained a Buy rating, implying 37.61% upside from the previous close. Analysts’ consensus rating is Moderate Buy, with an average target of $14.80.
• Xeris beat quarterly estimates, reporting EPS of $0.06 versus $0.03 expected and revenue of $107.23 million versus $101.68 million expected. The stock was reported up 25% on Friday.
• Two company insiders sold shares under pre-arranged Rule 10b5-1 plans, while retaining substantial holdings; insiders sold 148,332 shares worth about $1.41 million during the quarter.

Xeris Biopharma (NASDAQ:XERS - Get Free Report) had its price objective increased by investment analysts at HC Wainwright from $10.00 to $18.00 in a research report issued on Friday, Benzinga reports. The firm presently has a "buy" rating on the stock. HC Wainwright's price objective indicates a potential upside of 37.61% from the company's previous close.

Several other analysts have also recently commented on the company. Wall Street Zen raised Xeris Biopharma from a "hold" rating to a "buy" rating in a research report on Saturday, September 19th. Barclays upped their price target on Xeris Biopharma from $12.00 to $14.00 and gave the company an "overweight" rating in a research report on Tuesday, October 6th. Weiss Ratings lowered Xeris Biopharma from a "hold (c-)" rating to a "sell (d-)" rating in a research report on Tuesday, August 11th. Finally, Leerink Partners increased their price objective on Xeris Biopharma from $12.00 to $16.00 and gave the stock an "outperform" rating in a research note on Thursday, September 10th. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $14.80.

Xeris Biopharma Trading Up 25.0%

Xeris Biopharma stock opened at $13.08 on Friday. The company has a 50 day moving average price of $9.49 and a 200 day moving average price of $7.58. Xeris Biopharma has a 52 week low of $5.25 and a 52 week high of $13.74. The company has a debt-to-equity ratio of 17.00, a quick ratio of 1.02 and a current ratio of 1.45. The firm has a market capitalization of $2.38 billion, a price-to-earnings ratio of -118.91 and a beta of 0.61.

Xeris Biopharma (NASDAQ:XERS - Get Free Report) last posted its quarterly earnings data on Thursday, November 5th. The company reported $0.06 earnings per share for the quarter, topping the consensus estimate of $0.03 by $0.03. Xeris Biopharma had a negative net margin of 5.12% and a positive return on equity of 338.21%. The firm had revenue of $107.23 million for the quarter, compared to analysts' expectations of $101.68 million. Research analysts forecast that Xeris Biopharma will post 0.07 EPS for the current year.

Insider Buying and Selling at Xeris Biopharma

In other Xeris Biopharma news, insider Beth Hecht sold 25,000 shares of the company's stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $10.23, for a total value of $255,750.00. Following the transaction, the insider owned 1,086,130 shares in the company, valued at approximately $11,111,109.90. This represents a 2.25% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Steven Pieper sold 5,000 shares of the stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $10.23, for a total transaction of $51,150.00. Following the completion of the sale, the insider owned 1,346,053 shares of the company's stock, valued at approximately $13,770,122.19. The trade was a 0.37% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 148,332 shares of company stock worth $1,409,221. 4.35% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Xeris Biopharma

A number of hedge funds have recently modified their holdings of XERS. Knights of Columbus Asset Advisors LLC bought a new position in Xeris Biopharma during the third quarter valued at approximately $1,275,000. StoneX Group Inc. bought a new stake in Xeris Biopharma in the third quarter worth approximately $142,000. Pictet Asset Management Holding SA grew its position in Xeris Biopharma by 13.7% in the third quarter. Pictet Asset Management Holding SA now owns 34,107 shares of the company's stock worth $326,000 after acquiring an additional 4,108 shares in the last quarter. AlphaCentric Advisors LLC grew its position in Xeris Biopharma by 4.2% in the third quarter. AlphaCentric Advisors LLC now owns 48,489 shares of the company's stock worth $464,000 after acquiring an additional 1,940 shares in the last quarter. Finally, Commonwealth Equity Services LLC grew its position in Xeris Biopharma by 3.6% in the third quarter. Commonwealth Equity Services LLC now owns 213,337 shares of the company's stock worth $2,040,000 after acquiring an additional 7,482 shares in the last quarter. 42.75% of the stock is owned by institutional investors and hedge funds.

Key Xeris Biopharma News

Here are the key news stories impacting Xeris Biopharma this week:

• Positive Sentiment: Q3 results topped estimates: Xeris reported earnings of $0.06 per share versus the approximately $0.03 consensus, and revenue of $107.23 million versus estimates of $101.68 million. Earnings also improved from break-even a year earlier. Xeris Biopharma Reports Third Quarter 2026 Financial Results and Business Highlights
• Positive Sentiment: Long-term commercial potential: CEO John Shannon said Recorlev could approach $1 billion in annual sales three to four years earlier than previously expected. Xeris also updated its FY2030 earnings guidance; the provided report does not specify the revised figures. Xeris CEO sees Recorlev nearing $1B in annual sales
• Negative Sentiment: Insider selling: Three insiders sold a combined 45,000 shares at $10.23 each. The sales were conducted under pre-arranged Rule 10b5-1 plans, and the sellers retained substantial holdings, which may temper the signal. Xeris Biopharma insider share sale

About Xeris Biopharma

Xeris Biopharma, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for patients with endocrinology, gastroenterology and other serious or chronic conditions. The company uses proprietary formulation and delivery technologies designed to make complex therapies more stable, convenient and suitable for self-administration.

Xeris' commercial portfolio includes Gvoke, a ready-to-use glucagon injection for the treatment of severe hypoglycemia in adults and children with diabetes; Recorlev (levoketoconazole), an oral therapy for endogenous hypercortisolemia associated with endogenous Cushing's syndrome; and Keveyis (dichlorphenamide), a treatment for primary periodic paralysis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.